Hetero's COVID-19 oral drug gets WHO prequalification

WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission

Hetero unveils new logo and corporate brand identity

The new logo is a refreshing change from the version that has served Hetero well for three decades. And yet its reflection can be seen in the new version

Hetero gets CDSCO approval to manufacture and sell Sputnik Light in India

Sputnik Light is the first component of Sputnik V

CanSinoBIO's Convidecia approved as heterologous booster in China

Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants

Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation

Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study

DGCI approves Hetero’s Tocilizumab

Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month

BMS unveils new data highlighting sustained efficacy and safety of Sotyktu in psoriatic arthritis and lupus

Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions

CPHI & PMEC India 2025 to see participation of 2,000+ exhibitors

The event will be attended by 35,000+ industry professionals

European Commission approves Lilly’s Kisunla for treatment of early Alzheimer’s patients

Corbion and Kuehnle join forces to develop natural Astaxanthin from algae fermentation

Astaxanthin is a powerful antioxidant and red-orange carotenoid pigment found in various aquatic organisms